RT Journal Article
SR Electronic
T1 SARS-CoV-2 genetic variations associated with COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20114546
DO 10.1101/2020.05.27.20114546
A1 Pakorn Aiewsakun
A1 Patompon Wongtrakoongate
A1 Yuttapong Thawornwattana
A1 Suradej Hongeng
A1 Arunee Thitithanyanont
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.05.27.20114546.abstract
AB Herein, we performed a genome-wide association study on SARS-CoV-2 genomes to identify genetic variations that might be associated with the COVID-19 severity. 152 full-length genomes of SARS-CoV-2 that were generated from original clinical samples and whose patient status could be determined conclusively as either “asymptomatic” or “symptomatic” were retrieved from the GISAID database. We found that nucleotide variations at the genomic position 11,083, locating in the coding region of non-structural protein 6, were associated with the COVID-19 severity. While the 11083G variant (i.e. having G at the position 11,083) was more commonly found in symptomatic patients, the 11083T variant appeared to associate more often with asymptomatic infections. We also identified three microRNAs that differentially target the two variants, namely miR-485-3p, miR-539-3p, and miR-3149. This may in part contribute to the differential association of the two SARS-CoV-2 variants with the disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research project is supported by Mahidol University (MRC-IM 02/2563).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used in this study were retrieved from GISAID. The table of acknowledgement of the sequences used can be found in Table S1.